Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 4
2013 5
2014 4
2015 9
2016 10
2017 13
2018 12
2019 6
2020 15
2021 32
2022 27
2023 15
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.
Hauser RA, Videnovic A, Soares-da-Silva P, Liang GS, Olson K, Jen E, Rocha JF, Klepitskaya O. Hauser RA, et al. Parkinsonism Relat Disord. 2024 Apr 9;123:106971. doi: 10.1016/j.parkreldis.2024.106971. Online ahead of print. Parkinsonism Relat Disord. 2024. PMID: 38631081 Free article.
INTRODUCTION: In BIPARK-1 and BIPARK-2, addition of once-daily opicapone to levodopa/carbidopa significantly reduced daily "OFF"-time relative to placebo in adults with Parkinson's disease (PD) and motor fluctuations. ...At Week 14/15, mean decrease from baseline in ODNSP …
INTRODUCTION: In BIPARK-1 and BIPARK-2, addition of once-daily opicapone to levodopa/carbidopa significantly reduced daily "OFF"-time …
Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
Lee JY, Ma HI, Ferreira JJ, Rocha JF, Sung YH, Song IU, Ahn TB, Kwon DY, Cheon SM, Kim JM, Lee CS, Lee PH, Park JH, Lee JH, Park MY, Kim SJ, Baik JS, Choi SM, Shin HW, Lee HW, Kang SY, Jeon B. Lee JY, et al. Mov Disord Clin Pract. 2024 Apr 9. doi: 10.1002/mdc3.14030. Online ahead of print. Mov Disord Clin Pract. 2024. PMID: 38594812
RESULTS: The adjusted mean in absolute off time was significantly greater for opicapone 50 mg than for L-dopa 100 mg (-62.1 vs. -16.7 minutes; P = 0.0015). ...CONCLUSIONS: Opicapone 50 mg was more effective than an additional 100 mg L-dopa dose at decreasing off tim …
RESULTS: The adjusted mean in absolute off time was significantly greater for opicapone 50 mg than for L-dopa 100 mg (-62.1 vs. -16.7 …
Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
Wu W, Lu X, Zhang L, Hong D. Wu W, et al. Clin Neurol Neurosurg. 2024 Apr;239:108189. doi: 10.1016/j.clineuro.2024.108189. Epub 2024 Feb 23. Clin Neurol Neurosurg. 2024. PMID: 38437773 Review.
However, opicapone (25 mg, MD 4.0, 95%CrI: 1.1-7.5) and opicapone (50 mg, MD 5.1, 95%CrI: 2.2-8.7) statistically significant increase the total ON-time. opicapone and entacapone could increase the rate of ON-time >1 h when compared with placebo. ...We foun …
However, opicapone (25 mg, MD 4.0, 95%CrI: 1.1-7.5) and opicapone (50 mg, MD 5.1, 95%CrI: 2.2-8.7) statistically significant i …
Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients.
Ikenaka K, Kajiyama Y, Aguirre C, Choong CJ, Taniguchi S, Doi J, Wang N, Ajiki T, Ogawa K, Kakuda K, Kimura Y, Mochizuki H. Ikenaka K, et al. Pharmacol Res Perspect. 2024 Feb;12(1):e1174. doi: 10.1002/prp2.1174. Pharmacol Res Perspect. 2024. PMID: 38287715 Free PMC article.
Changes in the AST and ALT levels and ALT/AST were analyzed in the patients treated with LCIG before and after the therapy (n = 24) and in the patients treated with LCIG + Opicapone before and after Opicapone treatment (n = 12). We found vitamin B6 levels were signi …
Changes in the AST and ALT levels and ALT/AST were analyzed in the patients treated with LCIG before and after the therapy (n = 24) and in t …
HR/MS-based lipidome analysis of rat brain modulated by tolcapone.
Rebouta J, Dória L, Coelho A, Fonseca MM, Castilla-Fernández G, Pires NM, Vieira-Coelho MA, Loureiro AI. Rebouta J, et al. J Pharm Biomed Anal. 2024 Apr 15;241:115971. doi: 10.1016/j.jpba.2024.115971. Epub 2024 Jan 10. J Pharm Biomed Anal. 2024. PMID: 38266454
Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database.
Li J, Zelmat Y, Storck W, Laforgue EJ, Yrondi A, Balcerac A, Sommet A, Montastruc F. Li J, et al. J Affect Disord. 2024 Apr 1;350:452-467. doi: 10.1016/j.jad.2024.01.119. Epub 2024 Jan 18. J Affect Disord. 2024. PMID: 38244800
More than half of drugs of interest are from nervous system. Opicapone (ROR: 20.66 95 %CI: 15.62-27.33), and gadoversetamide (ROR 18.62, 95 %CI 9.63-35.95) were the drugs with the highest ROR. ...
More than half of drugs of interest are from nervous system. Opicapone (ROR: 20.66 95 %CI: 15.62-27.33), and gadoversetamide (ROR 18. …
Objective assessment of the effects of opicapone in Parkinson's disease through kinematic analysis.
Bologna M, Guerra A, Colella D, Birreci D, Costa D, Cannavacciuolo A, Angelini L, Paparella G, Antonini A, Berardelli A, Fabbrini G. Bologna M, et al. Neurol Sci. 2024 May;45(5):2035-2046. doi: 10.1007/s10072-023-07233-6. Epub 2023 Dec 13. Neurol Sci. 2024. PMID: 38091213 Free PMC article.
BACKGROUND: Opicapone (OPC) is a third-generation, selective peripheral COMT inhibitor that improves peripheral L-DOPA bioavailability and reduces OFF time and end-of-dose motor fluctuations in Parkinson's disease (PD) patients. ...
BACKGROUND: Opicapone (OPC) is a third-generation, selective peripheral COMT inhibitor that improves peripheral L-DOPA bioavailabilit …
Management of OFF condition in Parkinson disease.
Koch J. Koch J. Ment Health Clin. 2023 Dec 1;13(6):289-297. doi: 10.9740/mhc.2023.12.289. eCollection 2023 Dec. Ment Health Clin. 2023. PMID: 38058599 Free PMC article.
Some of these agents represent additional options to previously available drug classes, such as the catechol-O-methyl transferase (COMT) inhibitor, opicapone, and monoamine-oxidase B-inhibitor (MAO-B inhibitor), safinamide, as well as new dosage forms for available therape …
Some of these agents represent additional options to previously available drug classes, such as the catechol-O-methyl transferase (COMT) inh …
Opicapone for Parkinson's disease.
[No authors listed] [No authors listed] Aust Prescr. 2023 Aug;46(2):42. doi: 10.18773/austprescr.2023.012. Aust Prescr. 2023. PMID: 38053568 Free PMC article. Review. No abstract available.
139 results